VIR Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR) is expected to report earnings on February 3, 2027, after the market close. The consensus earnings estimate is a loss of $0.31 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -29.6% since its last earnings release on November 4, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Vir Biotechnology, Inc.
Vir Biotechnology Inc. is a clinical-stage immunology company. It is focused on combining immunologic insights to treat and prevent serious infectious diseases. The company's development pipeline consists of product candidates targeting the hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. Vir Biotechnology Inc. is based in San Francisco, United States.
Sector
Healthcare
Industry
Biotechnology
Held By 2 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.